Sarah Huber - PulmonxCorp Vice Sales
| LUNG Stock | USD 9.82 0.44 4.69% |
Executive
Sarah Huber is Vice Sales of PulmonxCorp
| Address | 700 Chesapeake Drive, Redwood City, CA, United States, 94063 |
| Phone | 650 364 0400 |
| Web | https://pulmonx.com |
PulmonxCorp Management Efficiency
The company has return on total asset (ROA) of (0.2052) % which means that it has lost $0.2052 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4617) %, meaning that it created substantial loss on money invested by shareholders. PulmonxCorp's management efficiency ratios could be used to measure how well PulmonxCorp manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.36. The current Return On Capital Employed is estimated to decrease to -0.42. At this time, PulmonxCorp's Asset Turnover is most likely to slightly decrease in the upcoming years.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Rebecca Williston | Rxsight | N/A | |
| Scott Gaines | Rxsight | N/A | |
| Nikolas Kerr | Si Bone | 52 | |
| Julie Andrews | Orthofix Medical | 53 | |
| Aaron Berutti | Treace Medical Concepts | 45 | |
| John Harris | Integer Holdings Corp | 64 | |
| Kelley Nicholas | Neuropace | N/A | |
| Dan Yarbrough | Orthofix Medical | N/A | |
| Julie Dewey | Treace Medical Concepts | 63 | |
| Alex Huang | Rxsight | N/A | |
| Irina Ridley | Neuropace | 38 | |
| Scot Elder | Treace Medical Concepts | 49 | |
| Badri Amurthur | LivaNova PLC | N/A | |
| Matthew III | LivaNova PLC | N/A | |
| Chris Williamson | Iradimed Co | N/A | |
| Maureen OConnell | Rxsight | N/A | |
| Doris Quackenbush | Axogen Inc | N/A | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Brian Dow | ProSomnus Common Stock | 55 | |
| Gordon Weber | SurModics | 61 | |
| Jennifer Boyer | Inogen Inc | N/A | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
PulmonxCorp Leadership Team
Elected by the shareholders, the PulmonxCorp's board of directors comprises two types of representatives: PulmonxCorp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PulmonxCorp. The board's role is to monitor PulmonxCorp's management team and ensure that shareholders' interests are well served. PulmonxCorp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PulmonxCorp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Williamson, President CEO | ||
| David Lehman, General Secretary | ||
| Geoffrey Rose, Chief Officer | ||
| Lauren Cristina, VP Adm | ||
| John McKune, VP Controller | ||
| Sri Radhakrishnan, Chief Officer | ||
| Mehul Joshi, Chief Officer | ||
| Jrme Erath, Senior Africa | ||
| Marcee Maroney, Vice Marketing | ||
| Derrick Sung, Chief Officer | ||
| Glendon French, President CEO | ||
| Sarah Huber, Vice Sales | ||
| Lisa Paul, Chief Officer |
PulmonxCorp Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PulmonxCorp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | 303.85 M | ||||
| Shares Outstanding | 38.81 M | ||||
| Shares Owned By Insiders | 4.67 % | ||||
| Shares Owned By Institutions | 92.80 % | ||||
| Number Of Shares Shorted | 1.73 M | ||||
| Price To Book | 2.59 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in PulmonxCorp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Complementary Tools for PulmonxCorp Stock analysis
When running PulmonxCorp's price analysis, check to measure PulmonxCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PulmonxCorp is operating at the current time. Most of PulmonxCorp's value examination focuses on studying past and present price action to predict the probability of PulmonxCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PulmonxCorp's price. Additionally, you may evaluate how the addition of PulmonxCorp to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is PulmonxCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PulmonxCorp. If investors know PulmonxCorp will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PulmonxCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 1.909 | Quarterly Revenue Growth 0.297 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of PulmonxCorp is measured differently than its book value, which is the value of PulmonxCorp that is recorded on the company's balance sheet. Investors also form their own opinion of PulmonxCorp's value that differs from its market value or its book value, called intrinsic value, which is PulmonxCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PulmonxCorp's market value can be influenced by many factors that don't directly affect PulmonxCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PulmonxCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if PulmonxCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PulmonxCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.